NHS England approves delayed-release treatment for rare kidney disease
NHS England, kidney disease, ultra-rare inherited disorder
NHS England has approved the routine commissioning of delayed-release mercaptamine bitartrate for eligible patients with nephropathic cystinosis, providing an additional …
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
August 9, 2026Cardiology, Cardiovascular Health, Diagnostics, Hospital Management, Modern Service Framework, NHS
By Sabina Syed and Ewan Maule The Cardiovascular Disease Modern Service Framework1(CVD MSF) begins with a familiar problem at a much …
Functional lung imaging offers new possibilities for respiratory care
August 9, 2026Data Capture Asthma & COPD, Computed tomography, Diagnostics, digital technologies, medical imaging
Advances in computed tomography (CT) technology are helping to reshape the diagnosis and management of chronic respiratory disease, with new …
Five Facts about cardiovascular disease
August 9, 2026Medical Communications Five Facts, HRT, cardiovascular disease, cvd
1 Cardiovascular disease (CVD) is an umbrella term for conditions affecting the heart and blood vessels, including coronary heart disease, …
Data integrity: the keystone for AI adoption, patient safety and organisational reputation
August 9, 2026Manufacturing and Production Devices, data quality, digital technologies, regulatory practice
By Gurdip Singh Artificial intelligence is rapidly moving from future aspiration to operational reality across the pharmaceutical and medical device …
Artificial hearts: a century of innovation
August 9, 2026cardiac surgery, medical technology, patient care, university research
By Professor Brian J Ford Artificial heart technology has advanced through decades of scientific persistence, engineering innovation and clinical collaboration. …
MHRA awards Innovation Passports to liver cancer and dementia medicines
August 7, 2026Innovation Passports, MHRA, liver cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that two investigational medicines targeting liver cancer and dementia with …
Scottish NHS hospital adopts light-activated therapy to reduce surgical infections
August 6, 2026light-activated therapy, nhs scotland, surgical infections
NHS Golden Jubilee has become the first hospital in Scotland to introduce a light-activated nasal therapy designed to reduce the …
Manchester launches nurse-led clinic to improve kidney transplant outcomes
August 5, 2026Chiesi UK and Ireland, NHS, kidney transplants, nurse-led clinic
Manchester University NHS Foundation Trust has launched a specialist nurse-led clinic designed to provide more personalised follow-up care for kidney …
Androlabs and Majorelle expand testosterone therapy into France
August 4, 2026Androlabs, Majorelle, hypogonadism, testosterone therapy
Androlabs has partnered with French men’s health specialist Majorelle to commercialise Testavan, a testosterone replacement therapy for adult men with …
Promatix secures Innovate UK funding to advance bispecific ADC programme
August 3, 2026Innovate UK funding, Promatix, bispecific ADC programme
Promatix Biosciences has secured funding through Innovate UK’s Biomedical Catalyst programme to support preclinical development of its lead bispecific antibody-drug …
Syntis Bio appoints Matthew Dallas as Chief Financial Officer
August 3, 2026Syntis Bio
Syntis Bio has appointed Matthew Dallas as Chief Financial Officer (CFO). Dallas brings more than 25 years of financial expertise …
NanoSomiX and Beckman Coulter Diagnostics collaborate on blood tests for neurodegenerative diseases
July 30, 2026Beckman Coulter Diagnostics, NanoSomiX, neurodegenerative diseases
NanoSomiX and Beckman Coulter Diagnostics have announced plans to collaborate on the development of next-generation immunoassays for neurodegenerative diseases using …
EMA selects TrialAssure anonymisation platform for clinical trial documents
July 30, 2026EMA, TrialAssure, clinical trials
TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency (EMA) for use as an …
Researchers develop new antifungal compounds with improved safety profile
July 29, 2026The University of Manchester, antifungal therapies, imperial college london
Researchers at Imperial College London and The University of Manchester have developed a new family of antifungal compounds that demonstrated …
Lonza and Engitix partner to develop next-generation antibody-drug conjugates
July 28, 2026Engitix, Lonza, antibody-drug conjugates
Lonza and Engitix have entered into a licensing agreement to support the development of antibody-drug conjugates (ADCs), combining Engitix’s extracellular …
Simris Group appoints Tiffany J Vora as Strategic Advisor
July 28, 2026Simris Group
Simris Group has appointed Tiffany J Vora as a Strategic Advisor. This follows the recent appointment of Andreas Pahl as …
Cizzle Biotechnology expands US rollout of lung cancer blood test
July 27, 2026Blood test, Cizzle Biotechnology, lung cancer
Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung cancer in Texas in the …
MHRA approves first lower-carbon beclometasone inhalers for asthma
July 24, 2026Research and Development MHRA, asthma, inhaler, lower carbon
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first pressurised metered dose inhalers (pMDIs) to use …
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
July 23, 2026CDMO, PolyPeptide, Samsung BioLogics, acquisition
Samsung Biologics has launched an all-cash public tender offer to acquire PolyPeptide Group in a deal valued at approximately CHF1.46bn, …
Novogenia breaks ground on personalised healthcare campus
July 23, 2026Research and Development Novogenia, R&D, healthcare, laboratory
Novogenia AG has broken ground on a new headquarters and laboratory campus in Hallwang, Austria, designed to expand its capabilities …
Latest content
Five Facts about cardiovascular disease
